Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,836 across all filing types
Latest filing 2026-06-17 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a periodic report filed by a foreign private issuer to the SEC under the Securities Exchange Act of 1934. It includes an Exhibit (3.1 Articles of Association). The text primarily consists of a cover page with issuer identification and a signature page, but does not contain substantive financial statements or detailed analysis. The document length is short (1555 characters), indicating it is likely a regulatory filing or notice rather than a full report. There is no content consistent with a full Annual Report (10-K), Interim Report (IR), or other detailed filings. Since the document is a Form 6-K report filing and provides minimal content beyond an exhibit and signature, it fits best into Regulatory Filings (RNS) as a general disclosure filing of a foreign issuer. It is not a report publication announcement since it is the filing itself and not merely stating a report is attached or available elsewhere.
2026-06-17 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 95% confidence The document is a corporate announcement from Genmab regarding a capital increase due to employee warrant exercise. It details the number of shares being issued, the exercise price, the total share capital after increase, and related regulatory references including the Danish Capital Markets Act. It primarily concerns share capital changes through the exercise of warrants which is a capital structure event. It does not contain financial statements, audit results, management analysis, dividend info, nor is it a meeting announcement or legal proceeding update. The text is about the mechanics and effects of a capital increase and thus fits the filing category related to capital changes. Therefore, the document should be classified under 'Share Issue/Capital Change' (SHA). The document length is ~4873 characters, which fits for an announcement explaining a capital change rather than just a brief mention or a short report publication announcement.
2026-06-16 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 95% confidence The document is an official company announcement regarding a capital increase due to the exercise of employee warrants. It specifies the details of the share increase, the exercise price, the number of shares issued, and the impact on the company's share capital. The length of the document (6436 characters) suggests it is not a mere announcement of report publication but an actual update about capital changes. The content matches the definition for a Share Issue/Capital Change (SHA) filing, as it relates specifically to changes in share capital resulting from employee warrant exercises. There is no comprehensive financial report or earnings discussion, so it is not an Annual Report or Earnings Release. The announcement is regulatory and formal but focuses on capital structure.
2026-06-16 English
6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, Genmab A/S, submitted to the SEC. It includes a reference to a company announcement dated June 16, 2026, regarding a capital increase as a result of employee warrant exercise. The content does not present detailed financial statements or comprehensive financial report data but rather appears to announce a financing-related event (capital increase). Form 6-K filings typically include interim updates or announcements by foreign issuers, commonly including financing activities. Given the focus on capital increase and employee warrant exercise, the document aligns with an update on capital changes or financing activities. There is no evidence this document is a full annual or quarterly report, nor just a voting or management change announcement. Therefore, the best fitting classification is Capital/Financing Update (CAP). The document has moderate length but contains no financial statements, consistent with a financing update rather than a full report.
2026-06-16 English
Major Shareholder Announcement
Major Shareholding Notification Classification · 100% confidence The document is a detailed notification form listing information about a major shareholding in a company. It includes specific data sections about voting rights, share capital percentages, notification reasons (acquisition or disposal of voting rights), the date a threshold was crossed, and details of the entities holding the shares. It references the Capital Markets Act and relates to crossing ownership thresholds. This matches the description of a 'Major Shareholding Notification' which is a report of changes in significant share ownership levels crossing regulatory thresholds. The length and detailed data confirm it is not a mere announcement or proxy statement. Therefore, the document fits best under the category 'Major Shareholding Notification' (MRQ).
2026-06-15 English
Major Shareholder Announcement
Major Shareholding Notification Classification · 100% confidence The document is titled 'Major Shareholder Announcement' and references the Danish Capital Markets Act Section 30, which pertains to notifications regarding voting rights in shares. It announces that Orbis Investment Management Limited holds 4.99% voting rights in Genmab A/S. The content is a disclosure of a significant shareholding percentage crossing a threshold. The document is relatively short (3911 characters) and primarily focuses on ownership percentage disclosure without financial results or management commentary. This fits the definition of a 'Major Shareholding Notification' rather than other categories such as Annual Report or Earnings Release.
2026-06-15 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.